Vincerx Pharma Faces Delisting Concerns, Files 8-K
Ticker: VINC · Form: 8-K · Filed: May 28, 2024 · CIK: 1796129
| Field | Detail |
|---|---|
| Company | Vincerx Pharma, Inc. (VINC) |
| Form Type | 8-K |
| Filed Date | May 28, 2024 |
| Risk Level | high |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.0001, $1.00 |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, listing-standards, corporate-action
TL;DR
Vincerx Pharma might get delisted, filing major updates on finances and corporate structure.
AI Summary
Vincerx Pharma, Inc. filed an 8-K on May 28, 2024, reporting events as of May 22, 2024. The filing indicates a notice of delisting or failure to meet continued listing standards, a transfer of listing, amendments to articles of incorporation or bylaws, a change in fiscal year, submission of matters to a vote of security holders, and financial statements with exhibits. The company was formerly known as LifeSci Acquisition Corp. and Vincera Pharma, Inc.
Why It Matters
This filing signals potential financial distress or non-compliance with exchange rules, which could significantly impact the company's stock trading and investor confidence.
Risk Assessment
Risk Level: high — The notice of delisting or failure to meet listing standards is a significant red flag for the company's financial health and operational viability.
Key Players & Entities
- Vincerx Pharma, Inc. (company) — Registrant
- LifeSci Acquisition Corp. (company) — Former company name
- Vincera Pharma, Inc. (company) — Former company name
- May 22, 2024 (date) — Earliest event reported date
- May 28, 2024 (date) — Filing date
FAQ
What specific listing rule or standard has Vincerx Pharma, Inc. failed to satisfy?
The filing indicates a 'Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard' but does not specify which particular rule or standard has been violated in this excerpt.
What is the reason for the potential transfer of listing mentioned in the filing?
The filing states a 'Transfer of Listing' as an item of information, but the specific reason for this transfer is not detailed in the provided text.
When was Vincerx Pharma, Inc. formerly known as LifeSci Acquisition Corp. and Vincera Pharma, Inc.?
The filing notes the date of name change from LifeSci Acquisition Corp. to Vincerx Pharma, Inc. was December 23, 2020, and from Vincera Pharma, Inc. to Vincerx Pharma, Inc. was also December 23, 2020 (implied by the sequence and context, though the exact date for Vincera Pharma is not explicitly stated as separate from the LifeSci change).
What is the fiscal year end for Vincerx Pharma, Inc.?
The fiscal year end for Vincerx Pharma, Inc. is December 31.
What are the key items reported in this 8-K filing?
The key items reported are a notice of delisting or failure to satisfy a continued listing rule, a transfer of listing, amendments to articles of incorporation or bylaws, a change in fiscal year, submission of matters to a vote of security holders, and financial statements and exhibits.
Filing Stats: 1,133 words · 5 min read · ~4 pages · Grade level 11.6 · Accepted 2024-05-28 16:06:33
Key Financial Figures
- $0.0001 — ange on which registered Common Stock, $0.0001 par value per share VINC The Nasdaq
- $1.00 — an the minimum bid price requirement of $1.00 per share. The Notice has no immediat
Filing Documents
- d767413d8k.htm (8-K) — 40KB
- d767413dex31.htm (EX-3.1) — 127KB
- 0001193125-24-148090.txt ( ) — 322KB
- vinc-20240522.xsd (EX-101.SCH) — 3KB
- vinc-20240522_lab.xml (EX-101.LAB) — 19KB
- vinc-20240522_pre.xml (EX-101.PRE) — 12KB
- d767413d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 3.1 Amended and Restated Bylaws, as amended as of May 23, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: May 28, 2024 VINCERX PHARMA, INC. By: /s/ Raquel E. Izumi Raquel E. Izumi President and Chief Operations Officer